Review Article
The Association between E326K of GBA and the Risk of Parkinson’s Disease
Table 1
The characteristics of all included publications.
| | First author, year | NOS | Genetic method | Country | Total number (Na) | Genotype (GG/GA/AA) | | Cases | Controls | Cases | Controls |
| | Bras, 2009 [10] | 9 | PCR and Sanger sequencing | Portugal | 230 | 430 | 228/2/0 | 427/3/0 | | Clark, 2007 [11] | 9 | PCR and Sanger sequencing | America | 278 | 179 | 277/1/0 | 178/1/0 | | Spitz, 2008 [12] | 8 | RFLP | Brazil | 65 | 267 | 64/1/0 | 267/0/0 | | Ziegler, 2007 [6] | 8 | PCR and Sanger sequencing | China | 92 | 92 | 74/18/0 | 92/0/0 | | Nichols, 2009 [13] | 8 | PCR and TaqMan allelic-discrimination assays | North America | 450 | 359 | 422/28/0 | 348/11/0 | | Kalinderi, 2009 [14] | 7 | NA | Greece | 172 | 132 | 171/1/0 | 131/1/0 | | Lesage, 2011 [4] | 7 | PCR and Sanger sequencing | France | 1391 | 391 | 1390/1/0 | 391/0/0 | | Lesage, 2011 [15] | 7 | NA | North Africa | 194 (193) | 177 | 192/1/0 | 176/1/0 | | Duran, 2013 [7] | 7 | PCR and Sanger sequencing | UK | 185 | 283 | 171/12/2 | 283/0/0 | | Yu, 2015 [16] | 8 | PCR and Sanger sequencing | China | 184 | 130 | 183/1/0 | 130/0/0 | | Han, 2016 [17] | 8 | PCR and Sanger sequencing | Canada | 225 | 110 | 221/4/0 | 106/4/0 | | Ran, 2016 [8] | 8 | Pyrosequencing | Sweden | 1625 (1540) | 2025 (1937) | 1450/90/0 | 1872/65/0 | | Crosiers, 2016 [18] | 8 | PCR and Sanger sequencing | Flanders-Belgian | 266 | 536 | 254/12/0 | 521/15/0 | | Jesús, 2016 [19] | 8 | HRM and direct resequening | Spain | 532 | 542 | 516/16/0 | 529/13/0 | | Barkhuizen, 2017 [20] | 8 | PCR and Sanger sequencing | South Africa | 105 | 40 | 100/5/0 | 39/1/0 |
|
|
NOS: Newcastle–Ottawa Scale; NA: not available; PD: Parkinson’s disease; anumber of patients whose sequencing results for E326K were available.
|
